BR112014032049A2 - citrato férrico e suplemento de ferro oral - Google Patents

citrato férrico e suplemento de ferro oral

Info

Publication number
BR112014032049A2
BR112014032049A2 BR112014032049A BR112014032049A BR112014032049A2 BR 112014032049 A2 BR112014032049 A2 BR 112014032049A2 BR 112014032049 A BR112014032049 A BR 112014032049A BR 112014032049 A BR112014032049 A BR 112014032049A BR 112014032049 A2 BR112014032049 A2 BR 112014032049A2
Authority
BR
Brazil
Prior art keywords
ferric citrate
iron supplement
oral iron
oral
supplement
Prior art date
Application number
BR112014032049A
Other languages
English (en)
Portuguese (pt)
Inventor
Poradosu Enrique
F Oliviero James Iii
Bentsur Ron
Original Assignee
Keryx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keryx Biopharmaceuticals Inc filed Critical Keryx Biopharmaceuticals Inc
Publication of BR112014032049A2 publication Critical patent/BR112014032049A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014032049A 2012-06-21 2013-06-21 citrato férrico e suplemento de ferro oral BR112014032049A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261662565P 2012-06-21 2012-06-21
US201361757229P 2013-01-28 2013-01-28
US201361801050P 2013-03-15 2013-03-15
US201361800618P 2013-03-15 2013-03-15
PCT/US2013/047134 WO2013192565A2 (en) 2012-06-21 2013-06-21 Use of ferric citrate in the treatment of chronic kidney disease patients

Publications (1)

Publication Number Publication Date
BR112014032049A2 true BR112014032049A2 (pt) 2017-07-25

Family

ID=49769729

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014032049A BR112014032049A2 (pt) 2012-06-21 2013-06-21 citrato férrico e suplemento de ferro oral

Country Status (18)

Country Link
US (3) US20130345303A1 (enExample)
EP (3) EP2863906B1 (enExample)
JP (4) JP2015535209A (enExample)
KR (2) KR20200103855A (enExample)
CN (2) CN104884055A (enExample)
AU (2) AU2013278000A1 (enExample)
BR (1) BR112014032049A2 (enExample)
CA (1) CA2876982A1 (enExample)
DK (1) DK3730136T3 (enExample)
EA (1) EA201590062A1 (enExample)
ES (2) ES2970050T3 (enExample)
HK (1) HK1214503A1 (enExample)
IL (1) IL236356A0 (enExample)
MX (1) MX2014015615A (enExample)
NO (1) NO2025048I1 (enExample)
PL (1) PL3730136T3 (enExample)
SG (2) SG10201805177PA (enExample)
WO (1) WO2013192565A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102573807A (zh) 2009-07-21 2012-07-11 凯克斯生物制药公司 柠檬酸铁剂型
TWI653043B (zh) * 2012-12-20 2019-03-11 瑞士商伊蘭科動物健康公司 新用途
ES2733493T3 (es) 2013-06-05 2019-11-29 Tricida Inc Polímeros de unión a protones para la administración oral
EP2856941B1 (en) * 2013-10-01 2020-11-25 Fresenius Medical Care Deutschland GmbH Method and apparatuses for determining a patient's daily loss of iron
SG11201603091QA (en) * 2013-11-04 2016-05-30 Keryx Biopharmaceuticals Inc Ferric citrate for reducing cardiac failure in chronic kidney disease patients
WO2015110968A1 (en) * 2014-01-23 2015-07-30 Lupin Limited Pharmaceutical grade ferric citrate and method for its production
US10172882B2 (en) 2014-06-22 2019-01-08 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
IL322207A (en) 2014-12-10 2025-09-01 Tricida Inc Proton-binding polymers for oral administration
CA2978073A1 (en) * 2015-03-04 2016-09-09 Keryx Biopharmaceuticals, Inc. Use of ferric citrate in the treatment of iron-deficiency anemia
CN104688706B (zh) * 2015-04-01 2017-07-14 成都欣捷高新技术开发有限公司 一种高载药量、快速溶出的枸橼酸铁组合物及其制备方法
WO2016162794A1 (en) * 2015-04-08 2016-10-13 Leiutis Pharmaceuticals Pvt Ltd Pharmaceutical compositions of ferric citrate
WO2016162888A1 (en) * 2015-04-09 2016-10-13 Actavis Group Ptc Ehf. Process for preparing pharmaceutical grade ferric citrate
MA44875A (fr) 2016-05-06 2019-03-13 Tricida Inc Compositions pour le traitement de troubles acido-basiques
JP7387435B2 (ja) 2017-09-19 2023-11-28 日本たばこ産業株式会社 過多月経患者及び／又は過多月経を伴う婦人科疾患を有する患者における鉄欠乏性貧血の予防及び／又は治療におけるクエン酸第二鉄の使用
WO2019090176A1 (en) 2017-11-03 2019-05-09 Tricida, Inc. Compositions for and method of treating acid-base disorders
WO2019236639A1 (en) * 2018-06-04 2019-12-12 Tricida, Inc. Method of treating acid-base disorders
AU2019370677B2 (en) 2018-10-29 2025-08-14 Pharmacosmos Holding A/S Treating iron deficiency with ferric carboxymaltose
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
WO2022251563A1 (en) 2021-05-27 2022-12-01 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
CN115024495B (zh) * 2022-06-27 2024-03-22 北京金康普食品科技有限公司 改善肾病患者钙磷代谢的营养组合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003185A1 (en) * 1996-07-19 1998-01-29 Nikken Chemicals Co., Ltd. Remedies for hyperphosphatemia
US5753706A (en) * 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
CN1600302A (zh) * 2003-09-22 2005-03-30 宝龄富锦生技股份有限公司 含有柠檬酸铁的医药组合物以及药用级柠檬酸铁及其制法和含有药用级柠檬酸铁的膳食营养品
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
JP5667343B2 (ja) 2005-08-18 2015-02-12 パニオン アンド ビーエフ バイオテック インコーポレーテッド 医薬グレードの第二鉄有機化合物、その使用およびその製造方法
CA2953964A1 (en) * 2006-01-06 2007-07-19 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron
CN105055446B (zh) 2006-01-30 2022-06-03 宝龄富锦生技股份有限公司 逆转、防止、延迟或稳定软组织钙化的方法
CN102573807A (zh) 2009-07-21 2012-07-11 凯克斯生物制药公司 柠檬酸铁剂型

Also Published As

Publication number Publication date
AU2013278000A1 (en) 2015-01-22
JP2020100638A (ja) 2020-07-02
HK1210013A1 (en) 2016-04-15
JP2022070945A (ja) 2022-05-13
EP3730136B1 (en) 2023-12-27
EP4335436A2 (en) 2024-03-13
EP4335436A3 (en) 2024-05-15
MX2014015615A (es) 2015-03-20
EP2863906A2 (en) 2015-04-29
EP2863906B1 (en) 2020-03-18
IL236356A0 (en) 2015-02-26
KR102150135B1 (ko) 2020-08-31
PL3730136T3 (pl) 2024-03-25
SG11201408521WA (en) 2015-01-29
AU2018203205B2 (en) 2020-03-12
ES2970050T3 (es) 2024-05-24
US20130345303A1 (en) 2013-12-26
JP2015535209A (ja) 2015-12-10
CN104884055A (zh) 2015-09-02
DK3730136T3 (da) 2024-01-22
KR20200103855A (ko) 2020-09-02
CN113244209A (zh) 2021-08-13
WO2013192565A3 (en) 2015-10-15
CA2876982A1 (en) 2013-12-27
ES2796254T3 (es) 2020-11-26
NO2025048I1 (no) 2025-11-06
EA201590062A1 (ru) 2016-02-29
SG10201805177PA (en) 2018-07-30
KR20150036131A (ko) 2015-04-07
HK1214503A1 (zh) 2016-07-29
EP3730136A1 (en) 2020-10-28
JP2018138562A (ja) 2018-09-06
US20150079168A1 (en) 2015-03-19
WO2013192565A2 (en) 2013-12-27
US20140234416A1 (en) 2014-08-21
AU2018203205A1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
BR112014032049A2 (pt) citrato férrico e suplemento de ferro oral
IL236616A0 (en) 5-aminotetrahydroquinoline-2-new carboxylic acids and their use
EP2544749A4 (en) MAGNETIC GUIDED CATHETER
IL235826A0 (en) Diazaspirocycloalkane and azaspirocycloalkane
PT2920167T (pt) Compostos de hidrazinil-indol e conjugados
BR302013001611S1 (pt) Configuração aplicada em ferro de passar
EP2867209A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USES
IL251974B (en) Antifibrosis compounds and their uses
GB201216649D0 (en) Agents and methods
ZA201405392B (en) Substituted phenylimidazopyrazoles and use thereof
GB2503963C (en) Patient garment
BR112014000255A2 (pt) composição de suplemento de ferro
SG11201504482VA (en) Beta-hexosyl-transferases and uses thereof
GB201220813D0 (en) Breath ease soother 2
SG11201502069SA (en) Beta-hydroxy-beta-methylbutryic acid- containing compositions and uses thereof
PL2895176T3 (pl) Związek pośredni Rywaroksabanu i jego wytwarzanie
FR2992526B1 (fr) Protege-col et protege-aisselles des chemises
PL2830587T3 (pl) Kompozycja o balansującym i ochronnym wpływie na skórę
FI10259U1 (fi) Kaislarauta
AP2015008228A0 (en) Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
GB201202536D0 (en) Oxidation reaction-II
GB201215414D0 (en) Composition and use
GB201219884D0 (en) New composition and preparation thereof
GB201222541D0 (en) Kiddibidet and pottibidet
IL218974A0 (en) Conaction bitwen coutch and playels

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2675 DE 12-04-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.